Immunome, Inc. $IMNM Holdings Boosted by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC raised its stake in Immunome, Inc. (NASDAQ:IMNM) by 3,513.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 80,426 shares of the company’s stock after acquiring an additional 78,200 shares during the period. Nisa Investment Advisors LLC owned 0.09% of Immunome worth $942,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in IMNM. Teacher Retirement System of Texas lifted its holdings in shares of Immunome by 6.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 18,548 shares of the company’s stock worth $172,000 after purchasing an additional 1,188 shares during the last quarter. Main Management ETF Advisors LLC lifted its stake in Immunome by 1.6% in the second quarter. Main Management ETF Advisors LLC now owns 76,944 shares of the company’s stock valued at $716,000 after buying an additional 1,248 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Immunome by 3.2% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 53,187 shares of the company’s stock valued at $470,000 after acquiring an additional 1,643 shares during the period. BNP Paribas Financial Markets grew its position in shares of Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after acquiring an additional 2,909 shares during the last quarter. Finally, Voya Investment Management LLC grew its position in shares of Immunome by 21.2% during the first quarter. Voya Investment Management LLC now owns 18,905 shares of the company’s stock worth $127,000 after acquiring an additional 3,305 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on IMNM shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research note on Wednesday, October 8th. Wall Street Zen raised Immunome from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Lake Street Capital increased their price objective on Immunome from $22.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Guggenheim lifted their target price on Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Finally, Truist Financial assumed coverage on Immunome in a research report on Monday, December 1st. They set a “buy” rating and a $36.00 price target for the company. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $31.00.

Insider Activity

In other Immunome news, insider Philip Tsai purchased 10,000 shares of the business’s stock in a transaction on Friday, December 19th. The stock was bought at an average cost of $20.49 per share, with a total value of $204,900.00. Following the acquisition, the insider owned 43,300 shares of the company’s stock, valued at $887,217. The trade was a 30.03% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Isaac Barchas sold 383,200 shares of Immunome stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the completion of the transaction, the director directly owned 2,031,181 shares in the company, valued at $44,157,874.94. This represents a 15.87% decrease in their position. The SEC filing for this sale provides additional information. Insiders bought a total of 68,518 shares of company stock worth $1,453,958 over the last 90 days. 7.69% of the stock is currently owned by company insiders.

Immunome Price Performance

Immunome stock opened at $22.85 on Friday. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $25.30. The stock has a market capitalization of $2.10 billion, a PE ratio of -7.75 and a beta of 2.22. The firm has a 50 day simple moving average of $19.69 and a 200-day simple moving average of $14.28.

Immunome (NASDAQ:IMNM) last released its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. On average, analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.